Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Skyepharma | LSE:SKP | London | Ordinary Share | GB00B3BFNB64 | ORD 100P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 443.00 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
16/3/2016 11:03 | Aceuk, large shareholders always have a clause in these merger /takeovers that if a higher offer came in they have the right to walk away from the agreement. SKP is now in play, i would be very surprised if others did not get involved here. | debbie_does_dallas_twice | |
16/3/2016 11:03 | I doubt HBM's support is absolute. If a higher offer came in, they would presumably consider it. | ![]() frazboy | |
16/3/2016 11:01 | Seems this has been rushed out to some extent, a falling VEC share price would look less and less attractive by the day..... | ![]() soundbuy | |
16/3/2016 10:59 | I guess having the support of HBM limits the attraction to an outsider? To an extent though the board is obliged to consider all proposals..... | ![]() soundbuy | |
16/3/2016 10:45 | What I find a little surprising is the lack of stock activity in Vectura. It will be a 60:40 split approximately in favour of Vectura yet SKP trades are getting on for £6 million and VEC less than half a million and no significant movement either way as though the merger will have little impact on them, if any. | ![]() alexchry | |
16/3/2016 10:40 | "The deal has been recommended by both boards and received support from HBM Healthcare Investments, which holds approximately 28.5 per cent of Skyepharma." I guess having the support of HBM limits the attraction to an outsider? | ![]() aceuk | |
16/3/2016 10:04 | ....Agreed, I'd be looking across the pond | ![]() soundbuy | |
16/3/2016 09:58 | SoundBuy, ...yep, Pacira would save themselves an opportunity costs fortune in licences and milestone payments and I'm sure Shire could absorb a little one... | ![]() stentorian | |
16/3/2016 09:56 | Must admit I'm disappointed, with no debt and strong growth I was looking forward to a continuation of the gains of the last few years, not sure now. It may make sense from a corporate view, but it seems like we've been shackled to a weaker partner, revenues are about half SKPs. Will have to consider my options on this.... | ![]() diesel | |
16/3/2016 09:51 | Well, thanks to skp. A wonderful multi bagger, and well done to those intelligent and brave enough to buy near the lows. Today's news - strange tbh. Particularly given CEO grant was building a strong reputation, and is now stepping down. I suspect the combined group will deliver decent long term returns, but it again takes out the most optimistic near term scenario for skp. | ![]() wigwammer | |
16/3/2016 09:49 | stentorian reckon some will be factoring this in.......... | ![]() soundbuy | |
16/3/2016 09:48 | great results, showing that they have a firm base going forward, at last... Think the merger is too early in SKP's cycle and premium too low... a merger brings about uncertainty as to whether the merged group will work well together... Now they have a firmer footing, I think they could do much better on their own... | ![]() sikhthetech | |
16/3/2016 09:45 | ...so now we know why they didn't announce the results at 7.00am. SKP is worth way more than 410.5p per share. Tantamount to financial rape. The management have sold us down the river. Takeover offers please. | ![]() stentorian | |
16/3/2016 09:09 | 'The United States as a priority' caught my eye in the merger announcement. I wonder if they are going to have another try with Flutiform. | ![]() alexchry | |
16/3/2016 09:06 | Maybe - I think the "compelling" offer put on the table is much [edited @9:47] too cheap. Vectura are gaining a lot of upside without having enjoyed SKP shareholders years of pain, and therefor very [edited @9:47] cheaply. | ![]() aceuk | |
16/3/2016 09:00 | Counter offer (from across the pond)? | ![]() soundbuy | |
16/3/2016 08:58 | small premium, but first reaction is disappointing and would have provided better value on its own - quite comfortably beat consensus earnings forecasts for 2015. That said, I need to look at Vectura properly - some undoubted synergies. Vectura on significantly higher PE rating, but much faster short term growth. | ![]() 18bt | |
16/3/2016 08:57 | Worth the wait, the performance is becoming predictable. | ![]() diesel | |
16/3/2016 08:54 | Another surprise, still trying to work out whether it is a pleasant surprise or not but it is the end of my hopes of a big takeover. | ![]() alexchry | |
16/3/2016 08:50 | Picked up a few weeks ago, results at first sight look stunning | gersemi | |
16/3/2016 08:48 | ...RNS out now | ![]() stentorian |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions